Document Detail


Metabolic therapy for the treatment of ischemic heart disease: reality and expectations.
MedLine Citation:
PMID:  18035928     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ischemic heart disease is a major cause of morbidity and mortality in the world. Most of the existing therapeutic strategies used to treat ischemic heart disease aim at either increasing the oxygen supply to the heart (thrombolysis, revascularization, angiotensin converting enzyme inhibition and antiplatelet therapy) or decreasing the oxygen demand of the heart (beta-blockers and nitrates). Despite the fact that a compromised energy supply to the heart muscle is central to the pathology of ischemic heart disease, therapeutic approaches that focus on altering cardiac energy metabolism have not seen major clinical use. Therapeutic strategies in which the efficiency of oxygen utilization by the heart is enhanced could theoretically benefit the ischemic heart, and could have an additive benefit to existing therapeutic strategies. The energy supply for the heart (in the form of ATP) is normally provided by the balanced metabolism of both fatty acids (major part) and carbohydrates (minor part) oxidation. During reperfusion, this balance is broken by the dramatic enhancement of fatty acid oxidation and attenuation of carbohydrate oxidation, which results in intracellular H(+) accumulation and Ca(2+) overload. This article reviews the alterations in cardiac energy metabolism that occur in the ischemic heart, and discusses the existing and proposed pharmacologic therapies to optimize the balance of fatty acids and carbohydrate oxidation for the treatment of ischemic heart diseases.
Authors:
Wei Wang; Gary D Lopaschuk
Related Documents :
18666738 - Post-cardiotomy circulatory support with the terumo baby-rx oxygenator in a newborn.
6404288 - Coronary haemodynamic effects of nifedipine. comparison with glyceryl trinitrate.
9420698 - The use of carbon 11-labeled acetate for assessment of aerobic metabolism.
19608488 - Haemodynamic effects, safety, and tolerability of haemoglobin-based oxygen carrier-201 ...
23769648 - Influence of arterial access site selection on outcomes in primary percutaneous coronar...
16308018 - Surgical ventricular remodeling for multiterritory myocardial infarction: defining a ne...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  5     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-11-26     Completed Date:  2008-01-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1123-34     Citation Subset:  IM    
Affiliation:
University of Alberta, 423 Heritage Medical Research Center, Edmonton, Alberta T6G 2S2, Canada. wwang3@ualberta.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Glucose / metabolism
Carbohydrate Metabolism
Energy Metabolism
Enzyme Inhibitors / therapeutic use*
Fatty Acids / metabolism*
Female
Humans
Male
Myocardial Ischemia / drug therapy,  metabolism*,  mortality
Myocardial Reperfusion Injury / metabolism
Myocardium / metabolism
Oxidation-Reduction / drug effects*
Risk Assessment
Sensitivity and Specificity
Survival Analysis
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/Enzyme Inhibitors; 0/Fatty Acids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neurological complications of coronary angiographic procedures.
Next Document:  Contemporary clinical management of atrial septal defects in the adult.